EpiEndo Pharmaceuticals has received regulatory and ethics approval to commence a Lipopolysaccharide (LPS) challenge clinical trial with its lead molecule EP395.
EP395 is an orally available macrolide or ‘Barriolide’ with reduced antimicrobial activity which aims to address the unmet medical need for a treatment for COPD (Chronic Obstructive Pulmonary Disease).
“Commencing this study is the next major milestone in the development of EP395. We look forward to the valuable data that it will generate which will be key as we plan the next phase of clinical development,” said EpiEndo’s Chief Medical Officer, Ginny Norris, in EpiEndo’s press release.
About the study
The study will be conducted in up to 48 healthy adults at the Hannover Medical School in Germany. The Principal Investigator is Professor Jens Hohlfeld, Director of Airway Research and Aerosol Medicine at the Fraunhofer Institute for Toxicology and Experimental Medicine. This proof of pharmacology study is designed to assess the effect of repeat oral doses of EP395 on inflammation in the lung induced by inhaled LPS.
The results of the study will give key data on the anti-inflammatory effects of EP395, states the company in the press release.
Photo of the EpiEndo team